Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:49 am
| PEG Ratio | 0.26 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹95.4 and a market capitalization of ₹776 Cr. The company’s revenue has shown a fluctuating trend, with reported sales of ₹1,207 Cr in March 2023, rising to ₹1,709 Cr in March 2024. However, the trailing twelve months (TTM) revenue stood at ₹428 Cr, reflecting a significant decline compared to the previous fiscal year. Quarterly sales figures also indicate variability, with quarterly sales peaking at ₹312.69 Cr in December 2022 before dropping to ₹289.71 Cr in September 2023. This instability in revenue generation may raise concerns regarding the sustainability of growth amidst a competitive environment. Furthermore, with a cash conversion cycle (CCC) of 112 days, the company may face challenges in efficiently managing its working capital, which could impede its operational performance going forward.
Profitability and Efficiency Metrics
Ind-Swift Laboratories’ profitability metrics reveal a challenging landscape. The operating profit margin (OPM) was reported at a meager 2.36%, significantly lower than typical sector benchmarks, indicating a struggle to maintain profitability amidst rising costs. The company experienced a net profit of ₹226 Cr, but its return on equity (ROE) stood at 18%, which is relatively low for the pharmaceutical sector, where higher returns are often expected. Additionally, the interest coverage ratio (ICR) was reported at 0.10x, signaling potential difficulties in meeting interest obligations. This is compounded by a net profit margin of 116.48% in March 2025, which appears inflated due to extraordinary income, raising questions about the sustainability of profit levels. Overall, while there are signs of profitability, the efficiency metrics suggest that the company must improve its cost management strategies to bolster its bottom line.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ind-Swift Laboratories shows a notable improvement in reserves, which rose to ₹1,104 Cr by March 2025, reflecting a healthy accumulation of retained earnings. The total borrowings have drastically reduced to ₹41 Cr, down from ₹862 Cr in March 2023, indicating a significant deleveraging effort that enhances financial stability. The price-to-book value (P/BV) ratio is at 0.49x, suggesting that the stock is trading below its book value, which could present an attractive entry point for value investors. In contrast, the company’s total liabilities decreased to ₹1,438 Cr, providing a stronger equity base. However, the return on capital employed (ROCE) at 3% reflects inefficiencies in utilizing capital effectively. The current ratio of 3.92x and quick ratio of 3.41x indicate a strong liquidity position, which affords the company flexibility in meeting short-term obligations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ind-Swift Laboratories indicates a diversified ownership structure, with promoters holding 39.49% of the company, a slight decrease from previous quarters. Foreign institutional investors (FIIs) have increased their stake to 14.80%, suggesting growing confidence from international investors. However, domestic institutional investors (DIIs) hold a mere 0.68%, which may reflect caution among local institutions regarding the company’s performance. The public holds 45.02% of the shares, indicating a significant retail investor presence. The total number of shareholders has risen to 43,780, signaling increased interest and participation in the company’s equity. This diversified ownership base can be beneficial for governance and strategic decision-making, but the relatively low DII participation may raise concerns about institutional support in times of volatility.
Outlook, Risks, and Final Insight
Ind-Swift Laboratories faces a mixed outlook, with several strengths and risks shaping its future. On the positive side, the company has successfully reduced its debt levels and significantly increased reserves, providing a buffer against potential downturns. However, the fluctuating revenue trends and low profitability metrics raise concerns about its operational efficiency and market competitiveness. Risks include dependency on a stable regulatory environment in the pharmaceuticals sector and potential challenges in sustaining revenue growth. With the ongoing volatility in the market, the company must focus on improving its cost structure and operational efficiency to enhance profitability. A successful turnaround strategy could position Ind-Swift Laboratories favorably in the market, while failure to address these challenges could lead to further declines in investor confidence and financial performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ind-Swift Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,497 Cr. | 413 | 479/192 | 93.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 39.5 Cr. | 27.0 | 29.1/17.0 | 94.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,140.56 Cr | 1,177.13 | 52.88 | 202.41 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 280.17 | 310.21 | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 124.66 | 138.24 | 152.73 |
| Expenses | 227.16 | 251.45 | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 131.31 | 147.44 | 149.13 |
| Operating Profit | 53.01 | 58.76 | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 |
| OPM % | 18.92% | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.33% | -6.66% | 2.36% |
| Other Income | 7.39 | 7.54 | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 |
| Interest | 23.98 | 23.98 | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 |
| Depreciation | 16.28 | 16.41 | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 |
| Profit before tax | 20.14 | 25.91 | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 |
| Tax % | 1.09% | 2.16% | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% |
| Net Profit | 19.88 | 25.34 | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 |
| EPS in Rs | 3.36 | 4.29 | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 152.73 Cr.. The value appears strong and on an upward trend. It has increased from 138.24 Cr. (Mar 2025) to 152.73 Cr., marking an increase of 14.49 Cr..
- For Expenses, as of Jun 2025, the value is 149.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 147.44 Cr. (Mar 2025) to 149.13 Cr., marking an increase of 1.69 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.60 Cr.. The value appears strong and on an upward trend. It has increased from -9.20 Cr. (Mar 2025) to 3.60 Cr., marking an increase of 12.80 Cr..
- For OPM %, as of Jun 2025, the value is 2.36%. The value appears strong and on an upward trend. It has increased from -6.66% (Mar 2025) to 2.36%, marking an increase of 9.02%.
- For Other Income, as of Jun 2025, the value is 14.58 Cr.. The value appears to be declining and may need further review. It has decreased from 220.34 Cr. (Mar 2025) to 14.58 Cr., marking a decrease of 205.76 Cr..
- For Interest, as of Jun 2025, the value is 1.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -26.76 Cr. (Mar 2025) to 1.15 Cr., marking an increase of 27.91 Cr..
- For Depreciation, as of Jun 2025, the value is 6.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.44 Cr. (Mar 2025) to 6.68 Cr., marking a decrease of 0.76 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.35 Cr.. The value appears to be declining and may need further review. It has decreased from 230.46 Cr. (Mar 2025) to 10.35 Cr., marking a decrease of 220.11 Cr..
- For Tax %, as of Jun 2025, the value is 16.52%. The value appears to be increasing, which may not be favorable. It has increased from 3.55% (Mar 2025) to 16.52%, marking an increase of 12.97%.
- For Net Profit, as of Jun 2025, the value is 8.77 Cr.. The value appears to be declining and may need further review. It has decreased from 222.27 Cr. (Mar 2025) to 8.77 Cr., marking a decrease of 213.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 36.67 (Mar 2025) to 1.45, marking a decrease of 35.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,709 | 562 | 428 |
| Expenses | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,403 | 581 | 452 |
| Operating Profit | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 306 | -19 | -24 |
| OPM % | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 18% | -3% | -6% |
| Other Income | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 476 | 305 | 264 |
| Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 104 | 3 | -15 |
| Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 80 | 24 | 20 |
| Profit before tax | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 598 | 258 | 235 |
| Tax % | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 10% | 3% | |
| Net Profit | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 539 | 250 | 226 |
| EPS in Rs | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 91.18 | 41.32 | 37.26 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 1022.92% | -53.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1477.08% | -1076.53% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:15 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,104.00 Cr.. The value appears strong and on an upward trend. It has increased from 745.00 Cr. (Mar 2024) to 1,104.00 Cr., marking an increase of 359.00 Cr..
- For Borrowings, as of Mar 2025, the value is 41.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 217.00 Cr. (Mar 2024) to 41.00 Cr., marking a decrease of 176.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 224.00 Cr.. The value appears to be improving (decreasing). It has decreased from 432.00 Cr. (Mar 2024) to 224.00 Cr., marking a decrease of 208.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 273.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 273.00 Cr., marking an increase of 81.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 51.00 Cr..
- For Investments, as of Mar 2025, the value is 213.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Mar 2024) to 213.00 Cr., marking an increase of 101.00 Cr..
- For Other Assets, as of Mar 2025, the value is 952.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,106.00 Cr. (Mar 2024) to 952.00 Cr., marking a decrease of 154.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
Notably, the Reserves (1,104.00 Cr.) exceed the Borrowings (41.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 89.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 32.54 | 71.24 | 8.10 | -0.36 | -0.53 |
| Diluted EPS (Rs.) | 32.53 | 71.24 | 8.10 | -0.36 | -0.53 |
| Cash EPS (Rs.) | 33.72 | 80.35 | 17.59 | 21.55 | 14.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 170.63 | 157.64 | 83.36 | 67.61 | 65.66 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 170.63 | 157.64 | 114.02 | 100.47 | 100.90 |
| Revenue From Operations / Share (Rs.) | 27.93 | 216.78 | 201.87 | 173.68 | 149.04 |
| PBDIT / Share (Rs.) | -0.41 | 50.70 | 43.92 | 39.98 | 34.36 |
| PBIT / Share (Rs.) | -1.60 | 41.68 | 34.33 | 18.07 | 19.77 |
| PBT / Share (Rs.) | 33.59 | 98.46 | 14.47 | 2.10 | 3.01 |
| Net Profit / Share (Rs.) | 32.54 | 71.33 | 8.00 | -0.35 | -0.52 |
| NP After MI And SOA / Share (Rs.) | 32.53 | 71.24 | 7.96 | -0.35 | -0.52 |
| PBDIT Margin (%) | -1.48 | 23.38 | 21.75 | 23.01 | 23.05 |
| PBIT Margin (%) | -5.72 | 19.22 | 17.00 | 10.40 | 13.26 |
| PBT Margin (%) | 120.26 | 45.41 | 7.16 | 1.20 | 2.02 |
| Net Profit Margin (%) | 116.48 | 32.90 | 3.96 | -0.20 | -0.35 |
| NP After MI And SOA Margin (%) | 116.45 | 32.86 | 3.94 | -0.20 | -0.35 |
| Return on Networth / Equity (%) | 19.06 | 45.19 | 9.54 | -0.53 | -0.80 |
| Return on Capital Employeed (%) | -0.90 | 26.09 | 14.13 | 7.36 | 7.86 |
| Return On Assets (%) | 15.54 | 36.13 | 2.60 | -0.11 | -0.17 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 1.51 | 2.10 | 2.25 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 1.73 | 2.35 | 2.56 |
| Asset Turnover Ratio (%) | 0.14 | 0.85 | 0.66 | 0.54 | 0.46 |
| Current Ratio (X) | 3.92 | 2.99 | 3.14 | 3.22 | 3.00 |
| Quick Ratio (X) | 3.41 | 2.94 | 1.96 | 1.94 | 1.81 |
| Inventory Turnover Ratio (X) | 3.08 | 2.67 | 1.52 | 1.33 | 1.23 |
| Interest Coverage Ratio (X) | 0.10 | 5.86 | 2.85 | 2.50 | 2.05 |
| Interest Coverage Ratio (Post Tax) (X) | 0.70 | 1.68 | 1.81 | 0.97 | 0.96 |
| Enterprise Value (Cr.) | 121.62 | 165.50 | 1173.71 | 1328.01 | 1424.06 |
| EV / Net Operating Revenue (X) | 0.98 | 0.12 | 0.97 | 1.28 | 1.60 |
| EV / EBITDA (X) | -66.67 | 0.55 | 4.47 | 5.55 | 6.93 |
| MarketCap / Net Operating Revenue (X) | 3.01 | 0.45 | 0.27 | 0.38 | 0.48 |
| Price / BV (X) | 0.49 | 0.62 | 0.66 | 0.98 | 1.10 |
| Price / Net Operating Revenue (X) | 3.01 | 0.45 | 0.27 | 0.38 | 0.48 |
| EarningsYield | 0.38 | 0.72 | 0.14 | -0.01 | -0.01 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 32.54. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.54, marking a decrease of 38.70.
- For Diluted EPS (Rs.), as of Mar 25, the value is 32.53. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.53, marking a decrease of 38.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 33.72. This value is within the healthy range. It has decreased from 80.35 (Mar 24) to 33.72, marking a decrease of 46.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.63. It has increased from 157.64 (Mar 24) to 170.63, marking an increase of 12.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.63. It has increased from 157.64 (Mar 24) to 170.63, marking an increase of 12.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 27.93. It has decreased from 216.78 (Mar 24) to 27.93, marking a decrease of 188.85.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.41. This value is below the healthy minimum of 2. It has decreased from 50.70 (Mar 24) to -0.41, marking a decrease of 51.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.60. This value is below the healthy minimum of 0. It has decreased from 41.68 (Mar 24) to -1.60, marking a decrease of 43.28.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.59. This value is within the healthy range. It has decreased from 98.46 (Mar 24) to 33.59, marking a decrease of 64.87.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 32.54. This value is within the healthy range. It has decreased from 71.33 (Mar 24) to 32.54, marking a decrease of 38.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.53. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.53, marking a decrease of 38.71.
- For PBDIT Margin (%), as of Mar 25, the value is -1.48. This value is below the healthy minimum of 10. It has decreased from 23.38 (Mar 24) to -1.48, marking a decrease of 24.86.
- For PBIT Margin (%), as of Mar 25, the value is -5.72. This value is below the healthy minimum of 10. It has decreased from 19.22 (Mar 24) to -5.72, marking a decrease of 24.94.
- For PBT Margin (%), as of Mar 25, the value is 120.26. This value is within the healthy range. It has increased from 45.41 (Mar 24) to 120.26, marking an increase of 74.85.
- For Net Profit Margin (%), as of Mar 25, the value is 116.48. This value exceeds the healthy maximum of 10. It has increased from 32.90 (Mar 24) to 116.48, marking an increase of 83.58.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 116.45. This value exceeds the healthy maximum of 20. It has increased from 32.86 (Mar 24) to 116.45, marking an increase of 83.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.06. This value is within the healthy range. It has decreased from 45.19 (Mar 24) to 19.06, marking a decrease of 26.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.90. This value is below the healthy minimum of 10. It has decreased from 26.09 (Mar 24) to -0.90, marking a decrease of 26.99.
- For Return On Assets (%), as of Mar 25, the value is 15.54. This value is within the healthy range. It has decreased from 36.13 (Mar 24) to 15.54, marking a decrease of 20.59.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.14. It has decreased from 0.85 (Mar 24) to 0.14, marking a decrease of 0.71.
- For Current Ratio (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 3.92, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 2. It has increased from 2.94 (Mar 24) to 3.41, marking an increase of 0.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 4. It has increased from 2.67 (Mar 24) to 3.08, marking an increase of 0.41.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 3. It has decreased from 5.86 (Mar 24) to 0.10, marking a decrease of 5.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 3. It has decreased from 1.68 (Mar 24) to 0.70, marking a decrease of 0.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 121.62. It has decreased from 165.50 (Mar 24) to 121.62, marking a decrease of 43.88.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.12 (Mar 24) to 0.98, marking an increase of 0.86.
- For EV / EBITDA (X), as of Mar 25, the value is -66.67. This value is below the healthy minimum of 5. It has decreased from 0.55 (Mar 24) to -66.67, marking a decrease of 67.22.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has increased from 0.45 (Mar 24) to 3.01, marking an increase of 2.56.
- For Price / BV (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 24) to 0.49, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has increased from 0.45 (Mar 24) to 3.01, marking an increase of 2.56.
- For EarningsYield, as of Mar 25, the value is 0.38. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.38, marking a decrease of 0.34.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 116.48%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.9% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.06% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.7 (Industry average Stock P/E: 52.88)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 116.48%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | investor@indswiftlabs.com http://www.indswiftlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. S P Sharma | Independent Director |
| Mr. Param Bir Singh | Independent Director |
| Dr. Ashwani Kumar Vig | Independent Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 23 November 2025) is 6.51 which is 93.55% lower the current market price of 101.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 820 Cr. market cap, FY2025-2026 high/low of 124/67.2, reserves of ₹1,104 Cr, and liabilities of 1,438 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 820 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 23 November 2025?
The current stock price of Ind-Swift Laboratories Ltd as on 23 November 2025 is 101.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is 124/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 27.7.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 160.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.